COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,845 Articles (22,553 medRxiv, 8,292 bioRxiv)

Most recent first Previous |  Page 1419: Articles 14181-14190  | Next

Predicted pH-dependent stability of SARS-CoV-2 spike protein trimer from interfacial acidic groups
Lobo, V. R., Warwicker, J.
10.1101/2021.06.06.447235 — Posted: 2021-06-11
A year of COVID-19 GWAS results from the GRASP portal reveals potential SARS-CoV-2 modifiers
Thibord, F., Chan, M. V., Chen, M.-H., Johnson, A. D.
10.1101/2021.06.08.21258507 — Posted: 2021-06-11
Adaptive vaccination may be needed to extirpate COVID-19: Results from a runtime-alterable strain-drift and waning-immunity model
Getz, W. M., Salter, R., Vissat, L. L., Koopman, J. S., Simon, C. P.
10.1101/2021.06.07.21258504 — Posted: 2021-06-11
Complement activation induces excessive T cell cytotoxicity in severe COVID-19
Georg, P., Astaburuaga-Garcia, R., Bonaguro, L., Brumhard, S., Michalick, L., Lippert, L. J., Kostevc, T., Gäbel, C., Schneider, M., Streitz, M., Demichev, V., Gemünd, I., Barone, M., Tober-Lau, P., Helbig, E. T., Stein, J., Dey, H.-P., Paclik, D., Mülleder, M., Aulakh, S. K., Mei, H. E., Schulz, A. R., Hippenstiel, S., Corman, V. M., Beule, D., Wyler, E., Landthaler, M., Obermayer-Wasserscheid, B., Boor, P., Demir, M., Wesselmann, H., Suttorp, N., Uhrig, A., Müller-Redetzky, H., Nattermann, J., Kuebler, W. M., Meisel, C., Ralser, M., Schultze, J. L., Aschenbrenner, A. C., Thibeault, C., Kurth, F., Sander, L.-E., Blüthgen, N., Sawitzki, B.
10.1101/2021.06.08.21258481 — Posted: 2021-06-11
Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study
Bahl, A., Johnson, S., Maine, G., Hernandez Garcia, M., Nimmagadda, S., Qu, L., Chen, N.-W.
10.1101/2021.06.09.21258617 — Posted: 2021-06-11 Discussion: Onsite
Identification of ACE2 modifiers by CRISPR screening
Sherman, E. J., Mirabelli, C., Tang, V. T., Khan, T. G., Kennedy, A. A., Graham, S. E., Willer, C., Tai, A. W., Sexton, J. Z., Wobus, C. E., Emmer, B. T.
10.1101/2021.06.10.447768 — Posted: 2021-06-10
Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
Abdoli, A., Aalizadeh, R., Aminianfar, H.
10.1101/2021.06.10.447951 — Posted: 2021-06-10 Discussion: Onsite
MPI8 is Potent Against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L
Ma, X. R., Alugubelli, Y. R., Ma, Y., Vatansever, E. C., Scott, D. A., Qiao, Y., Yu, G., Xu, S., Liu, W. R.
10.1101/2021.06.10.447950 — Posted: 2021-06-10
Evaluating the utility of high-resolution proximity metrics in predicting the spread of COVID-19
Mehrab, Z., Adiga, A., Marathe, M., Venkatramanan, S., Swarup, S.
10.1101/2021.06.07.21258492 — Posted: 2021-06-10
A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies
Panda, R., Castanheira, F. V. E. S., Schlechte, J., Surewaard, B. G., Shim, H. B., Zucoloto, A. Z., Slavikova, Z., Yipp, B. G., Kubes, P., McDonald, B.
10.1101/2021.06.07.21258484 — Posted: 2021-06-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).